Key result
Genetic and observational evidence links LDL-C and Lp(a) to aortic stenosis despite statins lacking benefit.
Design
Review
Genetic and observational links of Lp(a) to aortic stenosis should not change practice; randomized Lp(a)-lowering trials remain needed.
Schematic illustration of the observational and genetic evidence that LDL-cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] might be involved in the pathogenesis of aortic valve stenosis and/or aortic valve calcification. Recent trials with statins had no effect on the aortic valve outcomes. Questions concerning trials to be planned with Lp(a)-lowering drugs are listed. OxPL, oxidized phospholipids.
No takes yet. Share an insight, caveat, or question.
Florian Kronenberg (2022) studied this question. LDL-cholesterol and lipoprotein(a) are implicated in aortic valve stenosis pathogenesis by observational and genetic evidence, yet recent statin trials showed no effect on aortic valve outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: